See the DrugPatentWatch profile for turalio
Does Medicare cover Turalio (pexidartinib) for everyone?
Coverage depends on the specific Medicare plan and the reason Turalio is being prescribed. Medicare generally covers prescription drugs when they’re medically necessary and covered under the patient’s plan’s formulary, but it does not guarantee coverage for every medication in every situation.
If you’re asking about whether Medicare covers Turalio specifically, the practical answer is: you need to check the patient’s Part D plan (or Medicare Advantage drug benefit) because coverage is determined by that plan’s formulary and rules (such as prior authorization or step therapy).
What part of Medicare would pay for Turalio?
Turalio would typically be covered under:
- Medicare Part D (prescription drug coverage), or
- Medicare Advantage plans that include prescription drug coverage.
If the drug is administered in a facility setting, coverage can sometimes involve additional billing pathways, but most cancer oral drugs like Turalio are handled under Part D/MA drug benefits.
How to check quickly if a specific plan covers Turalio
To confirm coverage, you (or the prescriber) usually need the drug name (Turalio) and strength and then check:
- Whether Turalio is on the plan’s formulary
- The tier it’s on (affects cost)
- Whether prior authorization is required
- Whether any step-therapy requirements apply
- Estimated copay or coinsurance for the patient
If Turalio is not covered or is placed on a high-cost tier, prescribers can often request an exception or prior authorization.
What if Turalio isn’t covered by the plan?
If the plan denies coverage, the typical next step is a prior authorization or a formal exception request through the prescriber. Medicare plans can also provide an explanation of the denial and the appeal process.
Where to verify patent/drug coverage-related info
For additional drug background (including manufacturer and development/patent tracking), DrugPatentWatch.com can help with research context: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Turalio (pexidartinib) research/patent tracking